BR112023015462A2 - Compostos de sequestro para tratamento de transtorno por uso de substâncias e usos destes - Google Patents
Compostos de sequestro para tratamento de transtorno por uso de substâncias e usos destesInfo
- Publication number
- BR112023015462A2 BR112023015462A2 BR112023015462A BR112023015462A BR112023015462A2 BR 112023015462 A2 BR112023015462 A2 BR 112023015462A2 BR 112023015462 A BR112023015462 A BR 112023015462A BR 112023015462 A BR112023015462 A BR 112023015462A BR 112023015462 A2 BR112023015462 A2 BR 112023015462A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- sequestration
- document
- substance use
- use disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144441P | 2021-02-01 | 2021-02-01 | |
| PCT/US2022/014695 WO2022165407A1 (en) | 2021-02-01 | 2022-02-01 | Sequestration compounds for treatment of substance use disorder and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023015462A2 true BR112023015462A2 (pt) | 2023-10-10 |
Family
ID=82654907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023015462A BR112023015462A2 (pt) | 2021-02-01 | 2022-02-01 | Compostos de sequestro para tratamento de transtorno por uso de substâncias e usos destes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12569478B2 (https=) |
| EP (1) | EP4284506A4 (https=) |
| JP (1) | JP2024506861A (https=) |
| KR (1) | KR20230167020A (https=) |
| CN (1) | CN117858728A (https=) |
| AU (1) | AU2022213437A1 (https=) |
| BR (1) | BR112023015462A2 (https=) |
| CA (1) | CA3207013A1 (https=) |
| IL (1) | IL304837A (https=) |
| MX (1) | MX2023009055A (https=) |
| WO (1) | WO2022165407A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020245535B2 (en) | 2019-03-26 | 2022-06-30 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| CA3207013A1 (en) | 2021-02-01 | 2022-08-04 | Xinhua Li | Sequestration compounds for treatment of substance use disorder and uses thereof |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| AU2024303746A1 (en) * | 2023-06-16 | 2026-01-22 | Clear Scientific, Inc. | Sequestrant compounds for alpha 2 adrenergic agonists |
| WO2025184478A1 (en) * | 2024-03-01 | 2025-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Reversal agents for ultra-potent synthetic opioid-induced overdose and respiratory depression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375149T1 (de) * | 2003-07-25 | 2007-10-15 | Euro Celtique Sa | Behandlung von entzug |
| ES2702848T3 (es) * | 2011-02-23 | 2019-03-05 | Coeruleus Ltd | Complejos de flumazenil, composiciones que los comprenden y usos de los mismos |
| CA2875384A1 (en) * | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10874358B2 (en) * | 2015-12-22 | 2020-12-29 | Joseph Insler | Method and device for automatic identification of an opioid overdose and injection of an opioid receptor antagonist |
| IL312012A (en) * | 2016-11-18 | 2024-06-01 | Opiant Pharmaceuticals Inc | Compositions and methods for the treatment of opioid overdose |
| EP3833346A4 (en) * | 2018-08-08 | 2022-08-03 | Torralva Medical Therapeutics LLC | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| CA3134674A1 (en) * | 2019-04-04 | 2020-10-08 | Intra-Cellular Therapies, Inc. | Methods of treating neuropathic pain |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CA3207013A1 (en) | 2021-02-01 | 2022-08-04 | Xinhua Li | Sequestration compounds for treatment of substance use disorder and uses thereof |
-
2022
- 2022-02-01 CA CA3207013A patent/CA3207013A1/en active Pending
- 2022-02-01 AU AU2022213437A patent/AU2022213437A1/en active Pending
- 2022-02-01 CN CN202280024616.5A patent/CN117858728A/zh active Pending
- 2022-02-01 JP JP2023546560A patent/JP2024506861A/ja active Pending
- 2022-02-01 WO PCT/US2022/014695 patent/WO2022165407A1/en not_active Ceased
- 2022-02-01 BR BR112023015462A patent/BR112023015462A2/pt unknown
- 2022-02-01 MX MX2023009055A patent/MX2023009055A/es unknown
- 2022-02-01 EP EP22746860.0A patent/EP4284506A4/en active Pending
- 2022-02-01 KR KR1020237029974A patent/KR20230167020A/ko active Pending
- 2022-02-10 US US17/669,122 patent/US12569478B2/en active Active
-
2023
- 2023-07-30 IL IL304837A patent/IL304837A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022213437A9 (en) | 2024-07-11 |
| CN117858728A (zh) | 2024-04-09 |
| US20220313687A1 (en) | 2022-10-06 |
| CA3207013A1 (en) | 2022-08-04 |
| IL304837A (en) | 2023-09-01 |
| KR20230167020A (ko) | 2023-12-07 |
| AU2022213437A1 (en) | 2023-08-17 |
| EP4284506A4 (en) | 2024-12-25 |
| EP4284506A1 (en) | 2023-12-06 |
| JP2024506861A (ja) | 2024-02-15 |
| WO2022165407A1 (en) | 2022-08-04 |
| US12569478B2 (en) | 2026-03-10 |
| MX2023009055A (es) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015462A2 (pt) | Compostos de sequestro para tratamento de transtorno por uso de substâncias e usos destes | |
| UY30080A1 (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10 | |
| BRPI0513475A (pt) | derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc | |
| BRPI0519760A2 (pt) | derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasse | |
| CU20070156A7 (es) | Compuestos de quinolina heteroaromaticos y su uso como inhibidores de pde10 | |
| BRPI0714886B8 (pt) | sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| CL2008003578A1 (es) | Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc | |
| CR10358A (es) | Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos | |
| BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
| NI200700315A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos. | |
| ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
| ATE385497T1 (de) | 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten | |
| EA201270498A1 (ru) | 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс | |
| PA8624101A1 (es) | Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| NO20085398L (no) | Nye 1,4-diazabisyklo[3.2 2]nonyloksadiazolylderivater og deres medisinske anvendelse | |
| UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
| ATE463294T1 (de) | Verfahren zur konzentration und reinigung von biologischen verbindungen | |
| DK1377586T3 (da) | Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister | |
| CY1109792T1 (el) | Μεθοδος για την παρασκευη βρωμιουχου 3(r)-(2-υδροξυ-2,2-διθειενο-2-υλακετοξυ)-1-(3-φαινοξυπροπυλο)-1 - αζονιαδικυκλο [2.2.2] οκτανιου | |
| ATE450263T1 (de) | Diazabicyclische aryl-derivate als cholinerge rezeptor-modulatoren | |
| ATE481407T1 (de) | Neue diazabicyclische arylderivate und medizinische verwendung dafür | |
| DK1963323T3 (da) | Hidtil ukendte diazabicykliske arylderivater og medicinsk anvendelse heraf | |
| BRPI0923324A2 (pt) | Composto, uso de um composto, método para inibição da dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente, e, processo para preparar um composto. | |
| ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate |